Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders

Maria Sara Cipolat Mis, Simona Brajkovic, Francesco Tafuri, Nereo Bresolin, Giacomo P. Comi, Stefania Corti

Research output: Contribution to journalArticlepeer-review


The identification of the hexanucleotide repeat expansion (HRE) GGGGCC (G4C2) in the non-coding region of the C9ORF72 gene as the most frequent genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has opened the path for advances in the knowledge and treatment of these disorders, which remain incurable. Recent evidence suggests that HRE RNA can cause gain-of-function neurotoxicity, but haploinsufficiency has also been hypothesized. In this review, we describe the recent developments in therapeutic targeting of the pathological expansion of C9ORF72 for ALS, FTD, and other neurodegenerative disorders. Three approaches are prominent: (1) an antisense oligonucleotides/RNA interference strategy; (2) using small compounds to counteract the toxic effects directly exerted by RNA derived from the repeat transcription (foci), by the translation of dipeptide repeat proteins (DPRs) from the repeated sequence, or by the sequestration of RNA-binding proteins from the C9ORF72 expansion; and (3) gene therapy, not only for silencing the toxic RNA/protein, but also for rescuing haploinsufficiency caused by the reduced transcription of the C9ORF72 coding sequence or by the diminished availability of RNA-binding proteins that are sequestered by RNA foci. Finally, with the perspective of clinical therapy, we discuss the most promising progress that has been achieved to date in the field.

Original languageEnglish
Pages (from-to)4466-4476
Number of pages11
JournalMolecular Neurobiology
Issue number6
Publication statusPublished - 2017


  • Antisense oligonucleotides
  • Haploinsufficiency
  • Hexanucleotide repeat expansion

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders'. Together they form a unique fingerprint.

Cite this